Fund+
Venture capitalLeuven · Series A–Series B · 11 people tracked
Find your way into Fund+
1,069 people in our graph share verified history with the Fund+ team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Fund+ is an open-ended fund dedicated to long-term equity investment in innovative Life Sciences companies, with a particular focus on Belgium. It aims to create sustainable shareholder value, help build a leadership position within the Life Sciences sector, and generate meaningful, beneficial societal impact.
Source: firm website, verified Aug 3, 2026.
Team · 11 people
from the firm's website & public directories
What they invest in
from 16 of 22 portfolio companiesBiotech ×14Medical Devices ×13Healthtech ×8Deep Tech ×6Digital Health ×4AI & Machine Learning ×1Cloud Computing ×1Developer Tools ×1
HQs:Belgium×5United States×3Spain×2France×1Netherlands×1
Who they back
founder profiles across 11 portfolio companiesFounding team size:solo founder×72 founders×23 founders×14+ founders×1
Where their founders studiedfrom 11 founders with education data
Humboldt-Universität zu Berlin ×2Utrecht University ×2
What their founders studiedfrom 13 founders with field-of-study data
Life Sciences ×5Business & Management ×4Chemistry ×3Medicine ×3Economics ×2Engineering ×2
Where their founders worked beforefrom 15 founders with career history
UMC Utrecht ×3European Research Council (ERC) ×2Ghent University ×2UniD Manufacturing ×2VIB ×2
Investments · 22 tracked
founders shown can be your intro pathBy year:2022 · 12021 · 12020 · 35 dated
Biotechnology company developing orally available therapies for chronic inflammatory and autoimmune diseases.
BiotechNew York, US
Andreas Muehler(Executive Officer)inDaniel Vitt(Executive Officer, Director)inINDERPAL SINGH(Executive Officer)inHella Kohlhof(Executive Officer)inPatrick Walsh(Executive Officer)Aron Stern(Executive Officer)
Co-investorsBayern Kapitalbmp VenturesPontifax Venture CapitalOmega Funds
Astrivax Therapeutics is a clinical-stage biopharmaceutical company developing immunotherapies to treat virus-driven cancers, particularly HPV16-associated cancers like cervical and head and neck cancer.
BiotechDigital HealthHealthtechMedical Devices
Hanne Callewaert(Founder)in
Co-investorsKorysPMVV-Bio Ventures
Coave Therapeutics develops targeted gene therapy vectors using its proprietary ALIGATER platform to deliver therapeutic genes to specific tissues with improved safety and precision.
BiotechDeep TechHealthtechMedical DevicesParis, FR
Co-investorsKurma PartnersSeroba Life SciencesV-Bio VenturesBpifranceInvusNovo Holdings+1 more
VIB is a non-profit research institute focused on strategic basic research in life sciences, operating in partnership with five Flemish universities.
BiotechDeep TechMedical DevicesGhent, BE
Jan Steyaert(Founder (Scientific))inCedric Ververken(CEO)in
Co-investorsCapricorn Venture PartnersPMVQuest for GrowthV-Bio VenturesBioGeneration Ventures
Egle Therapeutics develops targeted immunotherapy drugs by leveraging regulatory T cell (Treg) biology to treat autoimmune diseases and cancer.
Biotech
Fiorella Kotsias(Chief Scientific Officer)inBernard Vanhove(Chief Development Officer)in
BoardMichel Detheux(Chairman)in
Co-investorsEQT Life SciencesJDRF T1D Fund
EPICS Therapeutics develops RNA epigenetics-based cancer treatments, focusing on METTL3 inhibitors for cancers including non-small cell lung cancer, pancreatic cancer, ovarian cancer, and colorectal cancer where existing therapies are insufficient.
BiotechDigital HealthMedical Devices
Co-investorsNewton Biocapital
Etherna is an RNA-LNP technology company that develops proprietary RNA chemistry and lipid nanoparticle delivery platforms for nucleic acid–based therapeutics, and partners with pharma and biotech organizations from early discovery through clinical development.
BiotechDeep TechMedical DevicesNiel, BE
Co-investorsPMVBoehringer Ingelheim Venture FundEQT Life SciencesNovalis LifeSciencesPWV
ExeVir develops multi-specific VHH antibody therapies to treat infectious diseases, immunological conditions, and oncology, with a focus on immunocompromised populations.
BiotechDeep TechDigital HealthHealthtechMedical DevicesGhent, BE
Xavier Saelens(Scientific Founder)Nico Callewaert(Scientific Founder)inMike Garrett(Chief Executive Officer)
Co-investorsV-Bio VenturesSambrinvestUCB VenturesVIBVIVES Partners
EyeD Pharma develops pharmaceutical treatments focused on ophthalmology, particularly for glaucoma and related eye conditions.
BiotechHealthtechMedical DevicesLiège, BE
Mélanie Mestdagt(Chief Executive Officer & Co-Founder)inMarc Foidart(Co-Founder)inJean-Marie Rakic(Co-Founder)
Co-investorsWallonie Entreprendre
Immunic is a clinical-stage biopharmaceutical company developing oral small molecule treatments for neurologic and autoimmune diseases with unmet medical needs.
BiotechHealthtechMedical DevicesNew York City, US
Dr. Hella Kohlhof(Co-Founder, Chief Scientific Officer)Erik Lundgren(Chief Executive Officer)inJason Tardio(President and Chief Operating Officer)inMichael A. Panzara(Chief Medical Officer)in
Indigo is developing an implantable continuous multi-metabolite monitoring (CMM) sensor based on silicon photonics that measures metabolites such as glucose, ketone, and lactate in real time, with data shown via a smartphone app.
Digital HealthHardwareMedical Devices
Danaë Delbeke(CTO and Founder)in
Co-investorsimec.xpand
Minoryx is a registration-stage biotech company developing novel therapies for severe, orphan genetic diseases of the central nervous system, with a lead compound (leriglitazone) in clinical trials for conditions including cerebral adrenoleukodystrophy, Friedreich's Ataxia, and Rett syndrome.
BiotechDeep TechHealthtechMedical DevicesMataró, ES
Marc Martinell(Co-Founder & Chief Executive Officer)in
Co-investorsChiesi VenturesCriteria Bio VenturesInvivo Capital PartnersKurma PartnersRoche Venture FundYsios Capital+2 more
Novadip develops regenerative medicine treatments using its 3M3 tissue regeneration platform to address conditions requiring bone and tissue repair, including spinal fusion, cancer recovery, and complex fractures.
BiotechDeep TechHealthtechMedical DevicesLouvain, BE
Dr. Denis Dufrane(Founder & Professor)in
BoardEric Paul Pâques(Chairman)
Co-investorsNew Science VenturesVIVES Partners
Ona provides cloud-based agent infrastructure that runs developer tasks in isolated environments while laptops are closed, automating workflow execution through events, schedules, and pull requests.
AI & Machine LearningCloud ComputingDeveloper Tools
Co-investorsBright Pixel CapitalCrane Venture PartnersPebblebedPreston-Werner VenturesAlta Life SciencesAsabys Partners+4 more
Ona Therapeutics develops therapeutic antibodies targeting lipid metabolism to treat advanced and metastatic cancers, including liposarcoma.
BiotechHealthtechMedical Devices
Co-investorsKorysMérieux Equity PartnersYsios CapitalAlta Life SciencesAsabys PartnersBpifrance+2 more
TargED is a biopharmaceutical company developing therapeutics for thrombotic disorders, spun out from University Medical Center Utrecht.
BiotechMedical DevicesUtrecht, NL
Coen Maas(Co-founder)inSteven de Maat(Chief Scientific Officer)inMarc van Moorsel(Director of Operations)inKristof Vercruysse(Chief Executive Officer)inRob Dekker(Vice President CMC)inFilip Van den Wyngaert(Vice President Asset Management)in
Co-investorsAndera PartnersCurie CapitalHadean VenturesRotripBioGeneration VenturesInkef+1 more
The page is a placeholder shell showing only cookie/consent notices for embedded third-party content (Vimeo, YouTube, reCAPTCHA, social media) and contains no substantive information about the company.
Dominik Schumacher(Founder)in
Co-investorsAndera PartnersAscenta CapitalBioMedPartnersFrazier Life SciencesNextech InvestOCCIDENT+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
CellaïonHoramaiTeos TherapeuticsMinoryxPromethera
Exits · 2
1 IPOs · 1 acquisitionsImmunicNASDAQ: IMUXTubulis GmbHacq. by Gilead Sciences
Portfolio news
latest coverage across their companiesImmunic · themarketsdaily.com · Aug 19, 2026
Ona Therapeutics · fiercebiotech.com · Aug 12, 2026
Ona · ddw-online.com · Jun 5, 2026
Coave Therapeutics · biopharminternational.com · May 26, 2026
iTeos Therapeutics · ad-hoc-news.de · May 21, 2026
Frequently asked questions
- How many investments has Fund+ made?
- Fund+ has 22 tracked investments, 2 of which have exited.
- What stage does Fund+ invest at?
- Fund+ invests at the Series A, Series B stages.
- What is Fund+'s typical check size?
- Fund+ typically writes checks of $5.5M – $16.5M.
- What sectors does Fund+ focus on?
- Fund+ focuses on Biotech, Healthtech, Impact & Social Good, Longevity, Medical Devices.
- Where is Fund+ located?
- Fund+ is headquartered in Leuven, BE.
- Who does Fund+ co-invest with?
- Fund+ most often shares deals with V-Bio Ventures, PMV, Criteria Bio Ventures, among 28 tracked co-investors.
Similar investors
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
The Dementia Discovery Fund (DDF), managed by SV Health Investors, is a family of specialized venture capital funds investing exclusively in companies developing or enabling novel therapeutics for dementia, including Alzheimer's Disease.
DOMiNO Ventures is a venture capital firm backing high-tech, pure-digital, globally ambitious founders with roots in Eastern Europe, Central Asia, and the Caucasus, including diaspora talent. It also runs the BetterFuture AI Acceleration Program and pursues impact-oriented Better Future Goals.
LIFTT is a venture capital holding company focused on deep tech technologies, using an operational, multi-vertical approach aimed at generating impact. It works to transform scientific research into high-impact companies, accelerating the path from lab to market.